Zai Lab, a Chinese biotech focused on oncology, autoimmune and infectious diseases, filed on Tuesday with the SEC to raise up to $115 million in an initial public offering.
The Shanghai, China-based company was founded in 2013 and plans to list on the Nasdaq under the symbol ZLAB. Zai Lab filed confidentially on May 31, 2017. J.P. Morgan, Citi and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
